Provided by Tiger Trade Technology Pte. Ltd.

Royalty Pharma plc

45.97
+0.13000.28%
Pre-market: 46.200.2300+0.50%08:42 EDT
Volume:2.40M
Turnover:110.30M
Market Cap:26.81B
PE:25.81
High:46.34
Open:45.91
Low:45.70
Close:45.84
52wk High:47.86
52wk Low:29.66
Shares:583.17M
Float Shares:379.85M
Volume Ratio:0.66
T/O Rate:0.63%
Dividend:0.90
Dividend Rate:1.96%
EPS(TTM):1.78
EPS(LYR):1.78
ROE:13.20%
ROA:5.15%
PB:4.14
PE(LYR):25.81

Loading ...

Royalty Pharma : Raised Full Year 2025 Guidance: Portfolio Receipts Expected to Be $3,200 to $3,250 Mln

THOMSON REUTERS
·
Nov 05, 2025

Royalty Pharma Buys $310 Million AMVUTTRA Royalty from Blackstone

Reuters
·
Nov 04, 2025

Royalty Pharma Keeps Quarterly Dividend at $0.22 a Share, Payable Dec. 10 to Holders of Record on Nov. 14

MT Newswires Live
·
Oct 17, 2025

Royalty Pharma plc Announces $0.22 Dividend for Q4 2025

Reuters
·
Oct 17, 2025

Citi Sticks to Its Buy Rating for Royalty Pharma (RPRX)

TIPRANKS
·
Oct 13, 2025

Royalty Pharma Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Oct 11, 2025

Royalty Pharma plc to announce third quarter 2025 financial results

Reuters
·
Oct 10, 2025

Zenas BioPharma Announces $120 Million Private Placement to Support Global Expansion and Development Programs

Reuters
·
Oct 08, 2025

Royalty Pharma: Strategic Positioning and Growth Potential Drive Buy Rating

TIPRANKS
·
Oct 02, 2025

Royalty Pharma Initiated at Buy by Goldman Sachs

Dow Jones
·
Sep 30, 2025

Royalty Pharma Appoints DR. Ted W. Love as Lead Independent Director

THOMSON REUTERS
·
Sep 29, 2025

Press Release: Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director

Dow Jones
·
Sep 29, 2025

1 Safe-and-Steady Stock with Promising Prospects and 2 We Ignore

stock_story_highlight
·
Sep 17, 2025

Citi Keeps Their Buy Rating on Royalty Pharma (RPRX)

TIPRANKS
·
Sep 16, 2025

BRIEF-Royalty Pharma Targets Mid-Teens Annual Shareholder Return Over Next 5 Years

Reuters
·
Sep 11, 2025

Royalty Pharma plc to Host Investor Day in New York City, Highlighting Strategic Plans and Market Growth

Reuters
·
Sep 11, 2025

Royalty Pharma Plc - Targets $4.7 Bln Portfolio Receipts or More by 2030

THOMSON REUTERS
·
Sep 11, 2025

Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation

THOMSON REUTERS
·
Sep 11, 2025

Royalty Pharma Unveils Comprehensive Deloitte Report Highlighting Biopharma Royalty Market Dynamics and Growth Prospects

Reuters
·
Sep 10, 2025